Royalty Pharma Completes $240M Deal for Full Evrysdi Royalty Rights

Royalty Pharma acquires complete royalty interest in Roche's Evrysdi for $240M upfront plus milestones, consolidating ownership of the 8-16% tiered royalty stream.